ArticleJournal of clinical microbiology2021
Development of a Measles and Rubella Multiplex Bead Serological Assay for Assessing Population Immunity.
Article in Journal of clinical microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Comparison of measles IgG enzyme immunoassays (EIA) versus plaque reduction neutralization test (PRNT) for measuring measles serostatus: a systematic review of head-to-head analyses of measles IgG EIA and PRNT.BMC infectious diseases · 2023Pooled it
- Immunogenicity and safety of a measles and rubella-containing vaccine at age 6 and 9 months in Bangladesh: an open-label, randomised trial.The Lancet. Child & adolescent health · 2025Trial
- A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial.Lancet (London, England) · 2024Trial
- Review
- Reconstructing pathogen-specific antibody binding epitopes and age-dependent immune signatures from proteomic-scale peptide libraries.Science advances · 2026Article
- Seroprotection to five vaccine-preventable diseases among children in East New Britain, Papua New Guinea.The Lancet regional health. Western Pacific · 2026Article
- Timing of antiretroviral treatment initiation and seropositivity to measles virus among children living with HIV in rural Zambia.medRxiv : the preprint server for health sciences · 2026Article
- Measles and rubella: From global health challenges to advancements in molecular diagnostics in the elimination era.Molecular therapy. Nucleic acids · 2025Review
- Multiplex bead assays enable integrated serological surveillance and reveal cross-pathogen vulnerabilities in Zambezia Province, Mozambique.Nature communications · 2025Article
- Testing for Antibodies to Four Parasites in Residual Blood Specimens from Trachoma Surveys in Kiribati, 2015-2019.The American journal of tropical medicine and hygiene · 2025Article
- High measles and rubella vaccine coverage and seroprevalence among Zambian children participating in a measles and rubella supplementary immunization activity.PLOS global public health · 2025Article
- A Multiplex Bead Serology Panel For Vaccine-Preventable Diseases Using Dried Blood Spots.Risk management and healthcare policy · 2025Article
- Measles-Rubella Microarray Patches Phase III Clinical Trial Framework: Proposal and Considerations.Vaccines · 2024Article
- The Global Measles and Rubella Laboratory Network Supports High-Quality Surveillance.Vaccines · 2024Article
- Article
- Serosurveillance for Measles and Rubella.Vaccines · 2024Review
- shinyMBA: a novel R shiny application for quality control of the multiplex bead assay for serosurveillance studies.Scientific reports · 2024Article
- Multiplex Bead Assay for the Serological Surveillance of Measles and Rubella.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Multiplex Serology for Measurement of IgG Antibodies Against Eleven Infectious Diseases in a National Serosurvey: Haiti 2014-2015.Frontiers in public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serosurveys are important tools for estimating population immunity and providing immunization activity guidance. The measles and rubella multiplex bead assay (MBA) offers multiple advantages over standard serological assays and was validated by comparison with the enzyme-linked immunosorbent assay (ELISA) and the measles plaque reduction neutralization (PRN) assay. Results from a laboratory-produced purified measles virus whole-virus antigen MBA (MeV WVA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.